Penetration and biological effects of topically applied cyclosporin A nanoparticles in a human skin organ culture inflammatory model

被引:28
作者
Frusic-Zlotkin, Marina [1 ]
Soroka, Yoram [1 ]
Tivony, Ran [2 ]
Larush, Liraz [2 ]
Verkhovsky, Lilian [1 ]
Bregegere, Francois Menahem [1 ]
Neuman, Rami [3 ]
Magdassi, Shlomo [2 ]
Milner, Yoram [1 ,4 ]
机构
[1] Hebrew Univ Jerusalem, Dept Biol Chem, Silberman Inst Life Sci, Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Inst Chem, Casali Ctr Appl Chem, IL-91904 Jerusalem, Israel
[3] Hadassah Hosp Ein Karem, Dept Cosmet Surg, Jerusalem, Israel
[4] Dead Sea & Arava Sci Ctr, Ein Gedi, Israel
关键词
cyclosporin A; cytokines; nanoparticles; psoriasis; skin organ culture; IN-VITRO; EPIDERMAL-KERATINOCYTES; PSORIATIC SKIN; DRUG-DELIVERY; EXPRESSION; MONOOLEIN; IL-20; VIVO;
D O I
10.1111/exd.12051
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Systemic antipsoriatic therapies have potentially life-threatening, long-term side effects. The efficacy of topical drugs is poor, but may be improved by the use of delivery systems based on drug nanoparticles. To produce nanoparticles (NP) composed of cyclosporin A, a classical antipsoriatic drug, and to investigate their penetration and biological effects in human skin affected by psoriatic symptoms, poly-e-caprolactone (PCL) and cyclosporin A (CsA) NP were prepared by the solvent evaporation method. Skin penetration was followed using fluorescently labeled NP in human skin organ cultures (hSOC). Psoriatic symptoms were mimicked in hSOC by the treatment with epidermal growth factor (EGF) and bacterial lipopolysaccharide (LPS). Cell viability in hSOC was evaluated by the resazurin test, and cytokine secretion into the growth medium was measured by immunodetection. We showed that topically applied NP diffused throughout the epidermis within two hours and through the dermis within the following day. They significantly reduced the secretion of inflammatory cytokines IL1 beta, IL6, IL8, IL20 and IL23. At active doses, no cytotoxicity was detected. This type of NP display relevant properties for the use as topical anti-inflammatory agents and may help to resorb psoriatic lesions.
引用
收藏
页码:938 / 943
页数:6
相关论文
共 29 条
  • [1] The use of ciclosporin in psoriasis
    Berth-Jones, J
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2005, 16 (5-6) : 258 - 277
  • [2] Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A
    Calvo, P
    Sanchez, A
    Martinez, J
    Lopez, MI
    Calonge, M
    Pastor, JC
    Alonso, MJ
    [J]. PHARMACEUTICAL RESEARCH, 1996, 13 (02) : 311 - 315
  • [3] Nanotechnology and the transdermal route A state of the art review and critical appraisal
    Cevc, Gregor
    Vierl, Ulrich
    [J]. JOURNAL OF CONTROLLED RELEASE, 2010, 141 (03) : 277 - 299
  • [4] Griffiths C E M, 1987, LANCET, V329, P806
  • [5] Inflammatory and hyperproliferative skin disease in mice that express elevated levels of the IL-1 receptor (type I) on epidermal keratinocytes - Evidence that IL-1-inducible secondary cytokines produced by keratinocytes in vivo can cause skin disease
    Groves, RW
    Rauschmayr, T
    Nakamura, K
    Sarkar, S
    Williams, IR
    Kupper, TS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (02) : 336 - 344
  • [6] Lecithin vesicular carriers for transdermal delivery of cyclosporin A
    Guo, JX
    Ping, QN
    Sun, GQ
    Jiao, CH
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 194 (02) : 201 - 207
  • [7] Amphiphilogels for drug delivery: Formulation and characterization
    Jibry, N
    Heenan, RK
    Murdan, S
    [J]. PHARMACEUTICAL RESEARCH, 2004, 21 (10) : 1852 - 1861
  • [8] Liu Hong-Zhuo, 2010, PDA J Pharm Sci Technol, V64, P191
  • [9] Investigation into the potential of low-frequency ultrasound facilitated topical delivery of Cyclosporin A
    Liu, Hongzhuo
    Li, Sanming
    Pan, Weisan
    Wang, Yongjun
    Han, Fei
    Yao, Huimin
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 326 (1-2) : 32 - 38
  • [10] Effect of vehicles and enhancers on the topical delivery of cyclosporin A
    Liu, HZ
    Li, SM
    Wang, YJ
    Yao, HM
    Zhang, Y
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 311 (1-2) : 182 - 186